Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 11752163 CER-001 therapy for treating kidney disease

Patent 11752163 was granted and assigned to Abionyx on September, 2023 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity

Disclosed herein is the use of CER-001, a negatively charged lipoprotein complex which comprises recombinant human apolipoprotein A-I (ApoA-I), sphingomyelin (SM), and 1,2-dihexadecanoyl-sn-glycero-3-phospho-(1′-rac-glycerol) (Dipalmitoylphosphatidyl-glycerol; DPPG) for treating kidney diseases, and methods for treating a subject having kidney diseases with CER-001. For example, the kidney disease can be associated with a lecithin cholesterol acyl transferase (LCAT) deficiency.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 11752163 CER-001 therapy for treating kidney disease

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo